SABS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SAB Biotherapeutics Inc (SABS) does not present a compelling buy opportunity for a beginner, long-term investor at this time. The lack of strong proprietary trading signals, weak financial performance, and hedge fund selling outweigh the positive analyst sentiment. It is recommended to hold off on investing until there are clearer signs of financial improvement or stronger trading signals.
The MACD is negative and contracting (-0.0167), indicating bearish momentum. RSI is neutral at 66.292, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 4.16), which may limit further upward movement in the short term.
Analysts have initiated coverage with Buy ratings and high price targets ($7 and $15), citing the potential of SAB-142 in pivotal development for Stage 3 Type 1 Diabetes, which could generate $2B in peak global sales if approved. The biotech sector is expected to recover in 2026, which could benefit SABS.
No recent news or congress trading data to support positive sentiment.
In Q3 2025, the company reported flat revenue growth (0% YoY), a significant drop in net income (-151.57% YoY), EPS (-106.25% YoY), and gross margin (-100% YoY). These metrics indicate poor financial health and lack of profitability.
Analysts from UBS and Guggenheim have initiated Buy ratings with price targets of $7 and $15, respectively. They highlight the potential of SAB-142 and the broader biotech recovery in 2026 as key drivers for future growth.
